Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.

@article{Morgensztern2016NivolumabAP,
  title={Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.},
  author={Daniel Morgensztern and Ronald Scott Herbst},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 15},
  pages={
          3713-7
        }
}
The outcomes for patients with previously treated advanced stage non-small lung cancer (NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care. Immunotherapy offers a novel approach for the treatment of these patients, with two anti-programmed death 1 (PD-1) checkpoint inhibitors, nivolumab and pembrolizumab, recently approved by the FDA based on large randomized clinical trials showing increased overall survival compared with standard second-line docetaxel… CONTINUE READING
Tweets
This paper has been referenced on Twitter 5 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Similar Papers

Loading similar papers…